Crossmark Global Holdings Inc. Buys 1,747 Shares of Humana Inc. (NYSE:HUM)

Crossmark Global Holdings Inc. raised its stake in shares of Humana Inc. (NYSE:HUMFree Report) by 9.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 21,092 shares of the insurance provider’s stock after purchasing an additional 1,747 shares during the period. Crossmark Global Holdings Inc.’s holdings in Humana were worth $9,657,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Rakuten Securities Inc. purchased a new position in shares of Humana during the 4th quarter valued at about $25,000. Gradient Investments LLC lifted its holdings in Humana by 200.0% during the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 40 shares in the last quarter. Cetera Trust Company N.A bought a new position in shares of Humana in the fourth quarter worth approximately $28,000. Private Wealth Management Group LLC purchased a new stake in shares of Humana in the fourth quarter worth $32,000. Finally, Carolinas Wealth Consulting LLC raised its position in shares of Humana by 274.1% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after purchasing an additional 74 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.0 %

NYSE HUM traded up $0.13 on Wednesday, hitting $361.00. 1,275,210 shares of the stock were exchanged, compared to its average volume of 1,904,287. Humana Inc. has a 52-week low of $298.61 and a 52-week high of $530.54. The firm has a market capitalization of $43.50 billion, a P/E ratio of 22.45, a P/E/G ratio of 2.14 and a beta of 0.53. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67. The stock has a fifty day moving average price of $330.26 and a two-hundred day moving average price of $365.13.

Humana (NYSE:HUMGet Free Report) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. The firm had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the company earned $9.38 EPS. Research analysts forecast that Humana Inc. will post 16 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 0.98%. Humana’s payout ratio is 22.04%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on HUM shares. Oppenheimer dropped their target price on shares of Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Bank of America lifted their target price on Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a research note on Monday, May 20th. Barclays cut their price objective on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a report on Tuesday, April 2nd. Raymond James assumed coverage on shares of Humana in a report on Friday, March 22nd. They issued a “market perform” rating on the stock. Finally, Robert W. Baird started coverage on shares of Humana in a research note on Thursday, May 30th. They set a “neutral” rating and a $374.00 target price for the company. Thirteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from, the stock currently has an average rating of “Hold” and a consensus price target of $423.63.

Get Our Latest Report on Humana

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

Want to see what other hedge funds are holding HUM? Visit to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.